Search

Displaying results 3961 - 3970 of 4207 in total
  1. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

  2. Drug

    Technetium Tc-99m ciprofloxacin

    go.drugbank.com/drugs/DB05488
    Experimental

    99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal absce...

  3. Drug

    Sulfaguanidine

    go.drugbank.com/drugs/DB13726
    Experimental

    Sulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.

  4. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...

  5. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  6. Drug

    Stem-cell derived exosome vesicle products

    go.drugbank.com/drugs/DB15743
    Experimental

    Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites.

  7. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  8. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...

  9. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system.

  10. Drug

    Abdavomeran

    go.drugbank.com/drugs/DB15695
    Investigational

    [L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027]